Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
US-2024352036-A1 · Oct 24, 2024 · US
Use of a bacterium isolated from the genus Pseudoalteromonas, cyclolipopeptides and uses thereof
US9956262B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9956262-B2 |
| Application number | US-201414893366-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 23, 2014 |
| Priority date | May 24, 2013 |
| Publication date | May 1, 2018 |
| Grant date | May 1, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to an isolated bacterium from the genus Pseudoalteromonas for its use as a probiotic, the use of said strain as a preservative, cyclolipopeptides which may be obtained from this bacterium, a composition comprising at least such a cyclolipopeptide, as well as to their uses.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treatment to improve animal breeding, which comprises the administration of an effective amount of an isolated bacterium Pseudoalteromonas hCg-6 , capable of producing cyclolipopeptides or formula A: wherein: R is selected from the group consisting of (a) alkyl groups comprising between 4 and 20 carbon atoms, except nonyl and undecyl groups; (b) alkylene groups comprising between 4 and 20 carbon atoms, except undec-4-ylene and tridec-6 -ylene groups; (c) alkyl groups substituted with an —OH group and comprising between 4 and 20 carbon atoms; and (d) alkylene groups substituted with an —OH group and comprising between 4 and 20 carbon atoms. 2. The method according to claim 1 , wherein the isolated bacterium is Pseudoalteromonas hCg-6 , a strain deposited according to the Budapest Treaty, on May 22, 2013, at the Collection Nationale de Culture de Microorganismes (CNCM, Paris, France) under the number I-4753. 3. The method of claim 1 , wherein the animal breeding occurs in aquaculture. 4. The method of claim 1 , wherein the animal is a fish, shellfish, crustacean, abalone or oyster.
Assignees
Inventors
Classifications
Local antiseptics · CPC title
Antibacterial agents · CPC title
Drugs for dermatological disorders · CPC title
Antibiotics · CPC title
the cyclisation not occurring through 2,4-diamino-butanoic acid · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9956262B2 cover?
- The present invention relates to an isolated bacterium from the genus Pseudoalteromonas for its use as a probiotic, the use of said strain as a preservative, cyclolipopeptides which may be obtained from this bacterium, a composition comprising at least such a cyclolipopeptide, as well as to their uses.
- Who is the assignee on this patent?
- Centre Nat Rech Scient, Univ Rennes, Univ Bretagne Occidentale, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K38/12. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).